Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving? [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Future perspectives on CAR-T therapy for multiple myeloma [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

COVID-19 vaccine effectiveness in patients with multiple myeloma and MGUS [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, summarizes the results of a study investigating the effectiveness of COVID-19 vaccination in patients with multiple myeloma and with monoclonal gammopathy of undetermined significance (MGUS). The study included two cohorts composed of vaccinated and matched unvaccinated patients with multiple myeloma and MGUS. Overall, the study reported that vaccine responses in patients with multiple myeloma and MGUS were limited compared to controls and to patients with other cancers, and that the benefit of the vaccine disappeared after six months. In addition, the effectiveness of the vaccine in patients with multiple myeloma was 5.6% compared to 27.2% in patients with MGUS. It was also found that the percentage of breakthrough infections in patients with multiple myeloma who received their last treatment three months before vaccination was higher than in patients who received their last treatment more than 6 months before vaccination. Therefore, it is still important for patients with multiple myeloma and MGUS to maintain social distancing measures. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Genomic characterization of non-progressor smoldering multiple myeloma [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the findings of a study investigating the genomic and transcriptomic features of patients with smoldering multiple myeloma who do not progress to multiple myeloma. Using whole-genome and transcriptome profiling in patients with smoldering multiple myeloma who had and had not progressed to multiple myeloma after a five-year follow-up, the study identified three characteristics of non-progressor smoldering multiple myeloma: a low mutational load, an absence of chromosome 8 copy number change, and a low deletion count. In addition, transcriptomic analysis highlighted that expression of MYC target genes and DNA repair pathway genes in non-progressor smoldering multiple myeloma cells was similar to normal plasma cells. Together with the recently defined genomic features of high-risk smoldering multiple myeloma, this genomic characterization will help select the right patient subgroups for clinical trials and provide assurance to patients with non-progressor smoldering multiple myeloma. It is important to validate these findings in a larger dataset. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.